Validated risk insights
Comprehensive WGS evaluates a curated list of rigorously qualified, clinically actionable variants in up to 151 genes across 40+ health conditions.

Atlas Curated Screen™ uses whole-genome sequencing (WGS) to identify genetic variants across a rigorously evidenced, curated set of genes linked to health conditions, to support proactive, personalized health decisions.
genes screened, depending on panel
health conditions covered
turnaround time from samples received
sample types accepted

Comprehensive whole-genome sequencing evaluates a curated list of rigorously qualified, clinically actionable variants in up to 151 genes across more than 40 health conditions. Every reported result guides personalized health decisions, like screening and lifestyle recommendations that support early detection and risk reduction.
As science advances, health changes, or tests are updated, whole-genome data can be reanalyzed for new insights — no new sample required.
Comprehensive WGS evaluates a curated list of rigorously qualified, clinically actionable variants in up to 151 genes across 40+ health conditions.
Every reported result guides personalized health decisions, like screening and lifestyle recommendations that support early detection and risk reduction.
As science advances, health changes, or tests are updated, whole-genome data can be reanalyzed for new insights — no new sample required.
Inherited cardiomyopathies and familial hypercholesterolemia.
Hereditary breast and ovarian cancer, and hereditary colorectal cancer.
Biotinidase deficiency, monogenic diabetes, and hereditary hemochromatosis.
Both Atlas options uncover actionable genomic insights. The difference is the sequencing method and number of genes analyzed.
Uses 30X whole-genome sequencing to detect actionable risk variants across 151 genes.
Uses high-coverage exome plus low-coverage whole-genome sequencing to detect actionable risk variants across 84 genes.
Because our Curated Screen test is a proactive risk screening tool performed in generally healthy individuals, we only report pathogenic and likely pathogenic variants to provide clear, clinically actionable results while avoiding unnecessary anxiety and confusion.
Result interpretation support is included in the form of clinician-to-clinician consultations for every patient.
MyOme offers genetic counseling to help with risk assessment and management for patients and their families.

Representative report page — not an actual patient result.
This test is intended for healthy (asymptomatic) adults as a screening tool.
From samples received, most results are delivered in 5 to 6 weeks. Follow-up testing or re-requisitions for existing MyOme patients are typically completed in under 2 weeks, often within a few days.
Turnaround times are estimates and begin once samples are processed at MyOme. They may be extended in cases outside MyOme's control, including delays related to confirmation testing or other unforeseen circumstances.
Patients with a personal or family history suggestive of a condition may require further screening or diagnostic genetic testing.
The test may not cover all potential genes or detect all variants associated with certain conditions. A patient may still be at risk of developing a condition even if the Curated Screen result is negative.
Genes omitted from this panel are those that do not yet meet our inclusion criteria. As data, technology, and guidelines evolve additional genes and associated conditions may be included.
We're here at every step — from ordering and sample collection to interpreting results with your patients.